Orphazyme A/S announced the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of Niemann-Pick disease Type C (NPC). The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved. The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved.